GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vor Biopharma Inc (NAS:VOR) » Definitions » Price-to-Owner-Earnings

Vor Biopharma (Vor Biopharma) Price-to-Owner-Earnings : (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Vor Biopharma Price-to-Owner-Earnings?

As of today (2024-05-17), Vor Biopharma's share price is $1.81. Vor Biopharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Vor Biopharma's Price-to-Owner-Earnings or its related term are showing as below:


VOR's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.34
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-17), Vor Biopharma's share price is $1.81. Vor Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.77. Therefore, Vor Biopharma's PE Ratio for today is At Loss.

As of today (2024-05-17), Vor Biopharma's share price is $1.81. Vor Biopharma's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.77. Therefore, Vor Biopharma's PE Ratio without NRI for today is At Loss.


Vor Biopharma Price-to-Owner-Earnings Historical Data

The historical data trend for Vor Biopharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vor Biopharma Price-to-Owner-Earnings Chart

Vor Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Vor Biopharma Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vor Biopharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Vor Biopharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vor Biopharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vor Biopharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Vor Biopharma's Price-to-Owner-Earnings falls into.



Vor Biopharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Vor Biopharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.81/-1.81
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vor Biopharma  (NAS:VOR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Vor Biopharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Vor Biopharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Vor Biopharma (Vor Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Cambridgepark Drive, Suite 101, Cambridge, MA, USA, 02140
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Executives
Eyal C. Attar officer: Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
5am Ventures Vi, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nathan D. Jorgensen officer: Chief Financial Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Christopher Slapak officer: Chief Medical Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Sadik Kassim officer: Chief Technology Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Tirtha Chakraborty officer: Chief Scientific Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Robert Ang director, officer: President and CEO C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Puretech Health Llc 10 percent owner 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107

Vor Biopharma (Vor Biopharma) Headlines